Essayer OR - Gratuit
The group's offerings range from over a billion injection doses annually to bespoke medical machinery
Express Pharma
|February 2025
Rishad Dadachanji, MD, Dadachanji Group speaks on the company's evolution from a pharma packaging company to a diversified solutions provider in biotechnology, automation, and sterile processing.
-

He highlights strategic collaborations, sustainability initiatives, and the group's vision for driving innovation in life sciences, in an interview with Express Pharma
How has the Dadachanji Group evolved from its inception in 1990 to its current diversified portfolio? How does the group ensure synergy between its diverse business verticals?
The Dadachanji Group has evolved significantly since its inception in 1990. Starting as Kaisha Manufacturers, which focused on pharma containers, the group gained prominence through innovation and a joint venture in 2008, becoming India's largest producer of ampoules, vials, syringes, and cartridges under Schott Kaisha. Following the divestment of this venture in 2021, the group diversified into multiple sectors, including biotechnology, medical devices, automation, robotics, and sterile processing, leveraging over 30 years of expertise to establish a broad and dynamic portfolio.
The synergy between the group's diverse business verticals is achieved through its unwavering commitment to innovation, quality, and customer-centricity. By emphasising cutting-edge technology and understanding market needs, the group creates solutions that align with global standards while addressing local challenges. A unified approach, driven by its leadership, ensures that the expertise and innovation from one sector inform and strengthen the others, creating an ecosystem of complementary capabilities and fostering growth across its varied ventures.
With over 30 years of expertise, the Dadachanji Group has established itself as a premium manufacturer of pharma products. Driven by innovation and cutting-edge technology, the group's offerings range from over a billion injection doses annually to bespoke medical machinery, emphasising both quality and scale.
Cette histoire est tirée de l'édition February 2025 de Express Pharma.
Abonnez-vous à Magzter GOLD pour accéder à des milliers d'histoires premium sélectionnées et à plus de 9 000 magazines et journaux.
Déjà abonné ? Se connecter
PLUS D'HISTOIRES DE Express Pharma

Express Pharma
Flexotherm Heating Tapes & Cords
Typical Applications of Heating Tapes and Cords in Industrial Solvent Handling
1 mins
October 2025

Express Pharma
DRIVING INDIA'S INNOVATION EDGE
Pharma leaders come together to highlight Bengaluru's R&D strength, tech ecosystem, and talent pool to power India Pharma Inc's shift from generics to innovation and global leadership
16 mins
October 2025

Express Pharma
Al compass: Transforming pharma commercialisation
As the world evolves at a rapid pace, pharma companies are embracing smarter approaches, leveraging Al across nearly every aspect of commercialisation, from market forecasting and personalised marketing to dynamic pricing and beyond. In this article, Neha Aathavale takes the pulse of the industry to explore who is taking note and how companies are beginning to put Al into action in their commercial operations
7 mins
October 2025

Express Pharma
PRIME NEO: New age doors from Gandhi Automation
Gandhi Automations presents the multi-composites, high-performance door PRIME NEO for clean environments. Complete Washable, Greater Sealing and Pressure Resistant.
1 mins
October 2025

Express Pharma
Unani Medicine: At crossroads of tradition and modernity
Manufacturers, academic institutions and research councils are working together to elevate Unani medicine through clinical validation and policy alignment with international standards, finds Swati Rana
7 mins
October 2025

Express Pharma
Single-Use Technologies in Biologics Manufacturing: Benefits, Challenges, and Growing Demand
The biopharmaceutical industry is increasingly adopting single-use technology (SUT) to achieve flexibility, cost efficiency, and faster time-to-market. Compared with stainless steel systems, SUT reduces capital investment, eliminates cleaning and sterilization steps, lowers contamination risk, and shortens production timelines.
1 min
October 2025

Express Pharma
Sustainable packaging with Romaco and Liveo Research
Recycable blister packs
3 mins
October 2025

Express Pharma
With India soon to be three times the population of the EU, it makes perfect sense to have manufacturing here
As part of Sweden's Focus Asia programme, a high-level SME delegation recently visited India to strengthen bilateral ties and explore collaborations across sectors including pharma, biotech and others. Building on the momentum of the \"Time for Sweden\" event, the visit underscored Sweden's commitment to innovation, sustainability, and co-creation with India. Among the delegation was Emil Alexander Byström, CEO of SpinChem AB, who in an interaction with Kalyani Sharma shared his insights on how advanced Swedish technologies like biocatalysis and the company's patented Rotating Bed Reactor (RBR) can accelerate India's pharma and biotech innovation journey while supporting sustainable growth.
3 mins
October 2025

Express Pharma
Cell therapy's next chapter: Industry embraces in-vivo innovation
Nikhil C Bhanumathi, Principal Clinical Lead, Thermo Fisher Scientific highlights that cell therapy is entering a bold new phase in 2025 as the industry shifts from complex, lab-based ex vivo CAR-T to faster, more accessible in vivo CAR-T innovations. This approach promises to expand access, lower costs, and potentially tackle solid tumors and autoimmune diseases
4 mins
October 2025

Express Pharma
Research misconduct ...can delay meaningful and reliable discoveries
Dr Gráinne McNamara, Research Integrity/Publication Ethics Manager, S. Karger AG explores how research misconduct, peer review fraud slow down pharma research. Of particular concern to India is the fact that India-based researchers constitute 5 per cent of articles in life sciences retracted between 1976-2023. India-based researchers also have one of the highest rates of retraction relative to the overall publication output. Over an email exchange with Viveka Roychowdhury, she details how publishers are now deploying AI tools, some of which contributed to the problem in the first place, to detect and avert fraudulent research submissions
6 mins
October 2025
Listen
Translate
Change font size